Physiometrix, Inc. Discloses Nasdaq Listing Deficiency NO. BILLERICA, Mass., May 25 /PRNewswire/ -- Physiometrix, Inc. (NASDAQ: PHYX) announced today that the company received a letter from Nasdaq on April 5, 2005, which cited the company's non-compliance with the requirement that the company maintain either shareholder equity of a minimum of $2,500,000 or $35,000,000 in listed securities or $500,000 of net income from continuing operations for two of the last three fiscal years, as required in marketplace rule 4310(c) (2)(B). Under these circumstances, the Nasdaq staff has reviewed the company's eligibility for continued listing. The company provided a plan of compliance to Nasdaq on April 20, 2005 to achieve and maintain compliance with all the Nasdaq Smallcap listing requirements. After review of this plan, Nasdaq has notified the company on May 18, 2005 that the plan submitted did not provide a definitive plan evidencing its ability to achieve near term compliance with the continued listing requirements or maintain such compliance over an extended period of time. Nasdaq therefore advised the company that, its securities are subject to delisting and will be delisted on May 27, 2005 unless the company requests an appeal and a hearing before the Nasdaq Listing Qualifications Panel. This will delay any delisting until the hearing date, which will be within 45 days of the date the company requests the hearing. The company filed the request for a hearing on May 23, 2005 and intends to continue activities designed to achieve compliance with the continued listing requirements in time to avoid delisting. Physiometrix Inc. designs, manufactures and markets noninvasive medical products -- based on novel gel materials, sophisticated signal-processing electronics technologies, and proprietary software -- for use in anesthesia- monitoring during surgical procedures. For more information, please visit the Company's Web site at http://www.physiometrix.com/. Statements in this press release regarding Physiometrix's growth and future business results of the Company are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual results to differ materially from any forward-looking statements made by the Company include, among others, revenue estimates, dependence on existing and future products, dependence upon third-party distribution and sales arrangements, the existence of alternative technologies and the potential emergence of new methods for consciousness monitoring, uncertainty of market acceptance, intense competition, partnership agreements, and government regulations, especially regulatory approvals. These and other relevant risks are described in the Company's Form 10-K dated March 31, 2005 filed with the SEC. The Company disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release. CONTACT: Daniel W. Muehl, CFO Physiometrix Inc. 978-670-2422 DATASOURCE: Physiometrix, Inc. CONTACT: Daniel W. Muehl, CFO of Physiometrix Inc., +1-978-670-2422 Web site: http://physiometrix.com/

Copyright